Talphera Asks the FDA to Let It Stop Trying
Enrollment fell 85–90% in three months, so a $54 million company with four quarters of cash has bet its timeline on a 45-day Sprint Meeting — and the stock already voted
TLPH · Earnings Call · 2026-11-12
The 45-day clock
Three months ago Talphera told investors the NEPHRO study of Niyad — an investigational nafamostat-based regional anticoagulant for the CRRT circuit — was past 75% enrolled and tracking to a second-half-2026 finish. On this call, the same 75% number appeared, but wrapped around a completely different story. Enrollment had collapsed. “Just compared with the same period in 2025, our number of patients consented and enrolled dropped by 85% to 90%.” — Shakil Aslam, Chief Medical Officer · 2026-11-12 The fix is procedural rather than clinical: management filed a briefing document requesting an FDA Sprint Meeting, a time-boxed 45-day feedback mechanism available to Breakthrough Device designees, to obtain the agency's agreement to close enrollment on December 31, 2026 at whatever N has accumulated. The company says the study is now over 80% powered for the primary endpoint versus the >90% it was designed for at 70 patients. This is a request for permission to stop early — early closure is the term that dominated the keyword set this quarter, and it is genuinely new vocabulary for this company. Ed Arce of WestPark Capital asked the question everyone was thinking:Vince Angotti's answer was that the company has enrolled patients "since our last update" and is "over 75% enrolled now without giving a specific number." That is not a denial.So just to clarify on the number of patients, 3 months ago you had reported 75% enrollment and today, 3 months later you're saying it's over 75%. So, am I to understand that over the last 3 months you've maybe enrolled 2 or 3 patients.
What the tape already knew
The company is worth $53.7 million. Its shares have fallen 37.9% over the last ninety trading days — a single leg down from a $1.47 August peak, now sitting 38% below it — before this print. The market reached a verdict on enrollment momentum ahead of the disclosure, which is what you would expect from a stock whose entire equity value is a probability-weighted bet on one readout. Note the symmetry: the $200 million peak US sales estimate management now touts is roughly four times the market capitalization of the company making the claim. Bull case and bear case are simply disagreeing about the discount rate. Cash is the reason the timeline matters so much. The balance sheet had $14.2 million at September 30, plus roughly $16 million of conditional tranches that management expects to close "around the time we release our top line data." That gate is not decorative. Effective net cash of $12M is down 87% from the 2018 peak of $94M, and a cash runway of about 4.4 quarters leaves roughly zero margin for a slow FDA negotiation. The burn is modest at least: operating loss of roughly $4M per quarter means the constraint is regulatory timing, not profligacy.The precedent trade
Give management this: the strongest part of the call was the specific precedent for stopping a CRRT trial early. Chief Medical Officer Shakil Aslam walked through three prior studies in this exact patient population — one Vantive/Baxter citrate study that enrolled 34 of a planned 160 over three years and was renegotiated down to 40 subjects, and Fresenius, which targeted 50 and settled for 31.That is a real regulatory datapoint, and it does some work: it argues the enrollment failure is a property of the indication — critically ill ICU patients with >50–60% mortality and narrow consent windows — not of Niyad or of Talphera's execution. The company reinforces it with the New England Journal study that was halted early on higher mortality with intermittent hemodialysis versus CRRT, which, if anything, expands the addressable CRRT pool. But the argument cuts both ways. If three separate sponsors over a decade could not enroll a CRRT study, and if citrate — with 25–30% off-label share of CRRT anticoagulation — could not pull 50 patients from its own user base, then the difficulty of clinical trial enrollment is at least weakly informative about the difficulty of commercial penetration into the same concentrated set of institutions. Angotti countered that the trial-to-market translation doesn't hold because of qualifying protocols and consent requirements. “Clinical trial environment really can't be translated into the real world due to the qualifying protocols, the consents required.” — Vincent Angotti, Chief Executive Officer · 2026-11-12 Plausible. Unproven. And the investor event that was supposed to detail the market research has slipped to the first quarter of 2027 — after the readout, not before.They reached back to the FDA and got their agreement to submit both their 510(k) as well as NDA... they were able to submit that data from those 31 subjects and they got approval of all of their products about 2 weeks ago.</inline_quote_placeholder>